PDCD1 and neoplasm: Targeting the specific chemokine receptor CXCR2 on MDSCs also prevented MDSCs recruitment to tumor tissues, treatment with the CXCR2 inhibitor SX-682 reduced MDSCs migration to TME and improved the efficacy of anti-PD1 therapy (Highfill et al., 2014).